CL2023002108A1 - Proteínas unión multiespecíficas se unen a cd33, nkg2d, cd16, métodos de uso. - Google Patents

Proteínas unión multiespecíficas se unen a cd33, nkg2d, cd16, métodos de uso.

Info

Publication number
CL2023002108A1
CL2023002108A1 CL2023002108A CL2023002108A CL2023002108A1 CL 2023002108 A1 CL2023002108 A1 CL 2023002108A1 CL 2023002108 A CL2023002108 A CL 2023002108A CL 2023002108 A CL2023002108 A CL 2023002108A CL 2023002108 A1 CL2023002108 A1 CL 2023002108A1
Authority
CL
Chile
Prior art keywords
binding proteins
multispecific binding
nkg2d
methods
proteins bind
Prior art date
Application number
CL2023002108A
Other languages
English (en)
Inventor
P Chang Gregory
F Cheung Ann
Grinberg Asya
Kam Sethi Dhruv
Haney William
Prinz Bianka
M Lunde Bradley
Wei Ronnie
Fallon Daniel
O'neil Steven
Original Assignee
Dragonfly Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dragonfly Therapeutics Inc filed Critical Dragonfly Therapeutics Inc
Publication of CL2023002108A1 publication Critical patent/CL2023002108A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen proteínas de unión multiespecíficas que se unen y matan células cancerosas humanas que expresan a CD33 (Siglec-3), así como composiciones farmacéuticas y métodos terapéuticos útiles para el tratamiento de cáncer que expresa CD33. La invención se refiere a proteínas de unión multiespecíficas que se unen a células cancerosas humanas que expresan CD33 y exhiben alta potencia y lisis máxima de células diana en comparación con anticuerpos monoclonales anti-CD33.
CL2023002108A 2018-02-20 2023-07-19 Proteínas unión multiespecíficas se unen a cd33, nkg2d, cd16, métodos de uso. CL2023002108A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862632756P 2018-02-20 2018-02-20
US201862677137P 2018-05-28 2018-05-28
CL2020002144A CL2020002144A1 (es) 2018-02-20 2020-08-19 Proteínas de unión multiespecíficas que se unen a cd33, nkg2d y cd16 y métodos de uso, (solic. hna 2143)

Publications (1)

Publication Number Publication Date
CL2023002108A1 true CL2023002108A1 (es) 2024-02-16

Family

ID=67688572

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2020002144A CL2020002144A1 (es) 2018-02-20 2020-08-19 Proteínas de unión multiespecíficas que se unen a cd33, nkg2d y cd16 y métodos de uso, (solic. hna 2143)
CL2023002108A CL2023002108A1 (es) 2018-02-20 2023-07-19 Proteínas unión multiespecíficas se unen a cd33, nkg2d, cd16, métodos de uso.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2020002144A CL2020002144A1 (es) 2018-02-20 2020-08-19 Proteínas de unión multiespecíficas que se unen a cd33, nkg2d y cd16 y métodos de uso, (solic. hna 2143)

Country Status (15)

Country Link
US (2) US20210101976A1 (es)
EP (1) EP3755721A4 (es)
JP (2) JP7353576B2 (es)
KR (1) KR20200132875A (es)
CN (1) CN112119093A (es)
AU (1) AU2019225741A1 (es)
BR (1) BR112020016939A2 (es)
CA (1) CA3091424A1 (es)
CL (2) CL2020002144A1 (es)
IL (1) IL276778A (es)
MX (1) MX2020008684A (es)
PE (1) PE20210110A1 (es)
SG (1) SG11202007945UA (es)
TW (1) TW201942134A (es)
WO (1) WO2019164930A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190118172A (ko) 2017-02-08 2019-10-17 드래곤플라이 쎄라퓨틱스, 인크. 천연 킬러 세포의 활성화를 위한 다중-특이적 결합 단백질 및 암 치료에서의 그의 치료적 용도
FI3582806T3 (fi) 2017-02-20 2023-09-07 Dragonfly Therapeutics Inc Her2:ta, nkg2d:tä ja cd16:ta sitovia proteiineja
KR20200118080A (ko) 2018-02-08 2020-10-14 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d 수용체를 표적화하는 항체 가변 도메인
TW201942134A (zh) * 2018-02-20 2019-11-01 美商蜻蜓醫療公司 結合cd33、nkg2d及cd16之多特異性結合蛋白及使用方法
CA3133333A1 (en) * 2019-04-30 2020-04-30 Brian Scott GARRISON Chimeric receptors and methods of use thereof
WO2021098851A1 (en) * 2019-11-20 2021-05-27 Eucure (Beijing) Biopharma Co., Ltd Anti-ctla4/ox40 bispecific antibodies and uses thereof
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
TW202332694A (zh) 2021-10-07 2023-08-16 英商阿凡克塔生命科學公司 血清半衰期延長之ｐｄ－ｌ１結合多肽
TW202334196A (zh) 2021-10-07 2023-09-01 英商阿法克塔生命科學有限公司 Pd-l1結合多肽
CN117482246A (zh) * 2022-12-30 2024-02-02 英百瑞(杭州)生物医药有限公司 抗cd33/cll1双特异性抗体-自然杀伤细胞偶联物及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012508017A (ja) * 2008-11-07 2012-04-05 ファブラス エルエルシー 抗ｄｌｌ４抗体及びその使用
TW201109438A (en) 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
DE102009045006A1 (de) * 2009-09-25 2011-04-14 Technische Universität Dresden Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen
SI2794658T1 (sl) * 2011-12-19 2017-05-31 Synimmune Gmbh Bispecifična molekula protitelesa
EP2951203B1 (en) 2013-03-15 2019-05-22 Xencor, Inc. Heterodimeric proteins
EP3954703A3 (en) * 2014-05-29 2022-05-18 MacroGenics, Inc. Tri-specific binding molecules and methods of use thereof
ES2688035T3 (es) * 2014-08-29 2018-10-30 Gemoab Monoclonals Gmbh Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
WO2016109774A1 (en) * 2015-01-02 2016-07-07 Dyax Corp. Bispecific antibodies against plasma kallikrein and factor xii
CN108602887B (zh) * 2015-10-02 2022-06-21 豪夫迈·罗氏有限公司 对共刺激性tnf受体特异性的双特异性抗体
EP3374389A1 (en) * 2015-11-13 2018-09-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti- nkg2d single domain antibodies and uses thereof
AU2017238172B2 (en) * 2016-03-21 2024-06-27 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
KR20190118172A (ko) * 2017-02-08 2019-10-17 드래곤플라이 쎄라퓨틱스, 인크. 천연 킬러 세포의 활성화를 위한 다중-특이적 결합 단백질 및 암 치료에서의 그의 치료적 용도
FI3582806T3 (fi) * 2017-02-20 2023-09-07 Dragonfly Therapeutics Inc Her2:ta, nkg2d:tä ja cd16:ta sitovia proteiineja
CN112040971A (zh) * 2018-02-08 2020-12-04 蜻蜓疗法股份有限公司 涉及激活天然杀伤细胞的多特异性结合蛋白的癌症联合疗法
EA202091976A1 (ru) * 2018-02-20 2021-07-06 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на cd33, и их применение
TW201942134A (zh) * 2018-02-20 2019-11-01 美商蜻蜓醫療公司 結合cd33、nkg2d及cd16之多特異性結合蛋白及使用方法
EA202091977A1 (ru) * 2018-05-28 2021-02-09 Драгонфлай Терапьютикс, Инк. Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
US20220378831A1 (en) * 2019-09-25 2022-12-01 Fate Therapeutics, Inc. Multi-targeting effector cells and use thereof
CN115836088A (zh) * 2020-05-06 2023-03-21 蜻蜓疗法股份有限公司 结合nkg2d、cd16和clec12a的蛋白质

Also Published As

Publication number Publication date
MX2020008684A (es) 2020-12-07
WO2019164930A1 (en) 2019-08-29
JP2023164908A (ja) 2023-11-14
PE20210110A1 (es) 2021-01-19
CL2020002144A1 (es) 2021-03-26
JP2021514396A (ja) 2021-06-10
US20220380459A1 (en) 2022-12-01
BR112020016939A2 (pt) 2020-12-15
TW201942134A (zh) 2019-11-01
CA3091424A1 (en) 2019-08-29
AU2019225741A1 (en) 2020-09-17
IL276778A (en) 2020-10-29
EP3755721A4 (en) 2021-12-22
CN112119093A (zh) 2020-12-22
JP7353576B2 (ja) 2023-10-02
KR20200132875A (ko) 2020-11-25
US20210101976A1 (en) 2021-04-08
SG11202007945UA (en) 2020-09-29
EP3755721A1 (en) 2020-12-30

Similar Documents

Publication Publication Date Title
CL2023002108A1 (es) Proteínas unión multiespecíficas se unen a cd33, nkg2d, cd16, métodos de uso.
EA202091977A1 (ru) Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
MX2019009468A (es) Proteínas de unión multiespecíficas para la activación de células asesinas naturales y usos terapéuticos de las mismas para tratar cáncer.
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
EA201790060A1 (ru) Биспецифические cd33- и cd3-связывающие белки
ZA202005259B (en) Anti-ctla4 antibodies and methods of making and using the same
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
EA201891732A1 (ru) Биспецифичные связывающие белки для pd-l1 и kdr
CO2022004757A2 (es) Proteínas que se unen a nkg2d, cd16 y flt3
AR122018A1 (es) Proteínas que se unen a nkg2d, cd16 y clec12a
EA201792581A1 (ru) Способы применения биспецифических cd33- и cd3- связывающих белков
CL2021000316A1 (es) Proteínas de unión multiespecíficas que se unen a bcma, nkg2d y cd16 y métodos de uso
EP4273258A3 (en) Proteins binding her2, nkg2d and cd16
CO2020001981A2 (es) Proteínas que se unen a nkg2d, cd16 y flt3
AR119746A1 (es) Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
NI201900034A (es) Anticuerpos que se unen a la proteína de envoltura del virus zika y uso de los mismos
EA202092302A1 (ru) Антитела к trem-1 и их применения
EA201992460A1 (ru) Антитела-агонисты btla и их применение
EA202090372A1 (ru) Универсальные соединения авт и их применение
MX2019009541A (es) Proteinas que se unen a psma, nkg2d y cd16.
EA202192488A1 (ru) Антитела против tsg-6 и их применения
MX2019009847A (es) Proteínas que se unen a cd123, nkg2d y cd16.
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use
AR127896A1 (es) Proteínas que se unen a nkg2d, cd16 y 5t4
EA202092947A1 (ru) Анти-pvrig/анти-tigit биспецифические антитела и способы их применения